Open AccessBiomarkers in the context of managing severe asthma
Author(s) -
Stanley J. Szefler
Publication year - 2019
Publication title -
journal of precision respiratory medicine
Language(s) - English
Resource type - Journals
eISSN - 2637-4277
pISSN - 2637-4269
DOI - 10.2500/jprm.2019.190009
Subject(s) - asthma , exhaled nitric oxide , medicine , intensive care medicine , context (archaeology) , precision medicine , personalized medicine , biomarker , asthma management , immunology , bioinformatics , pathology , spirometry , paleontology , biochemistry , chemistry , biology
Only recently have asthma strategies addressed biomarkers in asthma management, for example, as applied in the identification of severe asthmatics likely to respond to biologic therapy. Three biomarkers are readily available for clinical application in managing severe asthma including blood eosinophils, exhaled nitric oxide and serum IgE. While we have a limited number of biomarkers for clinical application, the available biomarkers have ushered in the era of personalized medicine for asthma. These three biomarkers are readily available for application in the clinic setting to select medications and to monitor response to treatment as well as medication adherence. These biomarkers can be used to modify the cost of uncontrolled asthma and also used to select those patients likely to respond to the available biologic therapies for severe asthma.